TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03223974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel DCB
Description: Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for \>30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES
Description: MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
Study: NCT04474743

Intervention type: OTHER
Intervention: No intervention - cross-sectional observational only
Description: No intervention - cross-sectional observational only

Intervention type: OTHER
Intervention: No intervention - cross-sectional observational only
Description: No intervention - cross-sectional observational only

Intervention type: OTHER
Intervention: No intervention - cross-sectional observational only
Description: No intervention - cross-sectional observational only

Intervention type: OTHER
Intervention: No intervention - cross-sectional observational only
Description: No intervention - cross-sectional observational only

Intervention type: OTHER
Intervention: No intervention - cross-sectional observational only
Description: No intervention - cross-sectional observational only
Study: NCT03493048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 130 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab, iv, 500mg/m2
Study: NCT04523571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection
Study: NCT03474731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Program (DSMP)
Description: The the Diabetes Self Management Program (DSMP) in a group setting: participants will attend a six week, evidence-based diabetes home self-management program. The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Patient Navigation (PN) only
Description: Tailored Patient Navigation (PN) only: trained Community Health Workers (CHW) will meet one-on-one with participants to assess the barriers experienced in adhering to medical appointments and will implement a navigation program accordingly.~The goal of this arm of the project is to try to get participants to attend recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSMP AND Tailored Patient Navigation
Description: DSMP AND Tailored Patient Navigation : patient navigation followed by 6 weeks of DSMP classes after the 3 month post-test interview.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Self-Management Program (DSMP) Delayed
Description: Groups randomized to DSMP Delayed will receive 6 weeks of DSMP classes after the 3 month post-test interview.~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization.
Study: NCT02568293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBCV
Description: SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as a control.
Study: NCT04415034

Intervention type: OTHER
Intervention: VAS and 5-D itch pruritus assessment
Description: All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
Study: NCT04568915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maitland Mobilization
Description: TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
Study: NCT00379080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tandutinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tandutinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tandutinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue samples
Description: Correlative studies
Study: NCT01983696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% oxygen concentration
Description: the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
Study: NCT00794248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days
Study: NCT01496950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10Hz active rTMS
Description: 10Hz active rTMS delivered to the left dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10Hz placebo rTMS delivered to the vertex
Study: NCT02760823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid (Thioctacid)
Description: 600 mg/12 hours, IV (in the vein)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Alpha Lipoic Acid)
Description: Normal saline in syringe simulating Alpha Lipoic Acid 600mg
Study: NCT02302638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture in different single-step media
Description: Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture in different single-step media
Description: Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
Study: NCT01295671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of beverages
Description: Home delivery of specified beverage type

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of beverages
Description: Home delivery of specified beverage type

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of beverages
Description: Home delivery of specified beverage type
Study: NCT02674958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
Study: NCT02492984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Xyntha
Description: Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
Study: NCT03313466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet cognitive behavioral therapy for insomnia (iCBTI)
Description: An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Class in sleeping well and improving insomnia
Description: A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
Study: NCT04128046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRFM injection
Description: Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
Study: NCT03685019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 degree flexion radiograph
Description: 20 degree flexion radiograph

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 degree flexion radiograph
Description: 20 degree flexion radiograph

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 degree flexion radiograph
Description: 45 degree flexion radiograph

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 degree flexion radiograph
Description: 45 degree flexion radiograph
Study: NCT00530400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: preoperative intravenous 1.5g cefuroxime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: preoperative intravenous placebo
Study: NCT03493048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab, iv, 500mg/m2
Study: NCT03546582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 targeted immunotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-precision radiotherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-precision radiotherapy
Study: NCT00682721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo two pills once daily
Study: NCT03493048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-FU 2400 mg/m² cont. inf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 2400 mg/m² cont. inf.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: leucovorin 200 mg/m²
Study: NCT00682721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 1 gram daily x number of days active in the study
Study: NCT02558933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate
Description: Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
Study: NCT03493048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: leucovorin 200 mg/m²
Study: NCT01652144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT7519M
Study: NCT00809887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micafungin lock therapy
Study: NCT00208390

Intervention type: DEVICE
Group type: OTHER
Intervention: Summit Tapered Hip System
Description: A cementless, tapered femoral component for use in total hip replacement
Study: NCT01851161

Intervention type: PROCEDURE
Intervention: computed tomography
Description: Undergo conventional CT scan in both supine and prone positioning

Intervention type: PROCEDURE
Intervention: 4-dimensional computed tomography
Description: Undergo 4D CT scan in both supine and prone positioning
Study: NCT00809887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin lock therapy
Study: NCT01851161

Intervention type: RADIATION
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT04530786

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia
Study: NCT04841278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS/ERCP
Description: EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
Study: NCT02509000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air purifier
Description: filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: air purifier
Description: filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
Study: NCT04198805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E [(all-rac)-α-tocopheryl acetate]
Description: Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
Study: NCT03511352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent sit-to-stands
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study: NCT04198805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid (DHA EE)
Description: DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
Study: NCT04523571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT01204684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor lysate-pulsed DC vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor lysate-pulsed DC vaccination+0.2% resiquimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Study: NCT04292912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 will be administered.
Study: NCT04198805

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]
Description: DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching soybean placebo (3 capsules) of all arms daily for 6 months.
Study: NCT03742700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Description: T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Description: E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Description: E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of the use of e-cigarette
Description: The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
Study: NCT00859079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human regular insulin intravenously
Description: Human regular insulin intravenously according to the Munich-registry.
Study: NCT00683644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsules taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsules taken once daily
Study: NCT03162575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
Study: NCT04436068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperfine MRI scan
Description: Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperfine MRI scan
Description: Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
Study: NCT03640650

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dropless Therapy
Description: The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
Study: NCT02703922

Intervention type: OTHER
Group type: OTHER
Intervention: color Doppler ultrasound and TAB in case of CDU negative
Description: Screening with color Doppler ultrasound followed by TAB in case of CDU negative
Study: NCT00818116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR Aspheric IOL
Description: Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
Study: NCT04255628

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET
Description: Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET
Description: Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
Study: NCT04835155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Premature Infant Oral Motor Intervention (PIOMI)
Description: The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
Study: NCT02549469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAY117031), 20% HPMC
Description: 1 tablet 660 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAY117031), 30% HPMC
Description: 1 tablet 660 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAY117031), 40% HPMC
Description: 1 tablet 660 mg administered orally once daily
Study: NCT03511352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand More
Description: Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
Study: NCT02549469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aleve (Naproxen Sodium, BAY117031)
Description: 1 tablet 220 mg administered orally three times daily
Study: NCT00810264

Intervention type: DEVICE
Intervention: CRT Therapy - LV Lead Registry
Description: Collecting long-term safety and efficacy data on a market-released left ventricular lead.
Study: NCT05873608

Intervention type: OTHER
Group type: OTHER
Intervention: Educational video
Description: Testing an educational video

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Undergo observation